A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
PHASE2
This phase 2b study will evaluate the efficacy and safety of 16 and 24 week...
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
PHASE2
This phase 2b study will evaluate the efficacy and safety of 16 and 24 week...
This Registry is designed to provide long term clinical and virologic follo...
Status
Completed
Location
Birmingham Gastroenterology Associates
Start Date
2012-04-13
Trial ID
NCT01457755
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
PHASE2
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-...
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
PHASE2
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Eval...
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
N/A
This Registry is designed to obtain long term data on participants who have...
Status
Completed
Location
Birmingham Gastroenterology Associates
Start Date
2011-12-19
Trial ID
NCT01457768
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
PHASE2
The purpose of this study is to compare the safety, tolerability and effect...
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
PHASE2
This a phase 2, randomized, open-label trial of GS-9256 plus GS-9190, two o...